Alar’s ketamine-based drug mitigates certain adverse events, which could eliminate the need for post-dose monitoring.
Alar Pharmaceuticals Inc. (Alar, TPEx:6785), a clinical-stage biopharmaceutical company focused on developing long-acting injectables (LAIs), today announced the positive results from its phase 1 ...
The word brings both fear and hope. We would like to offer support, structure, and clarity to those on the frontlines of neuropsychiatric care concerning the dangers of misuse of this scheduled ...
Ketamine-assisted psychotherapy (KAP) is rapidly emerging as a transformative tool in mental health treatment, offering profound benefits for conditions like depression, anxiety, and PTSD. As a ...
Treatment-resistant depression affects a large proportion of people with major depressive disorder, and while ketamine offers ...
Vietnam Investment Review on MSN
Alar reports positive Phase 1 results for long-acting ketamine therapy
TAICHUNG, April 6, 2026 /PRNewswire/ -- Alar Pharmaceuticals Inc. (Alar, TPEx:6785), a clinical-stage biopharmaceutical company focused on developing long-acting injectables (LAIs), today announced ...
Treatment completion was high (86.1%), with patients completing 5 or more infusions, with no adverse events reported. HealthDay News — Low-dose ketamine for chronic refractory pain shows therapeutic ...
The tragic early death of "Friends" star Matthew Perry from a ketamine overdose in 2023 has swung a spotlight on the dangers of unsupervised use of the potent anesthetic. Now, America's leading group ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results